Liver sinusoidal endothelial cell (LSEC) capillarization in NASH
Prof. Pierre-E.Rautou (France) discusses the effects of Liver Sinusoidal endothelial cell (LSEC) capillarization in patients with NASH. He also reviews the occurrences of LSEC capillarization at the early stages of NASH and its contribution to NASH progression by favoring inflammation and liver fibrosis. For the clinicians, he demonstrates a 24 week study of patients with NASH, exposed placebo and lanifibranor treatments strategies to determine LSEC changes.
Read MoreThe course of liver histology and morbi-mortality in NAFLD / NASH
Prof. Manuel Romero-Gomez discusses the course of liver histology and its impact on mortality and morbidity in patients with NAFLD and NASH. He clarifies how fibrosis determines the prognosis of NAFLD and is the main therapeutic target. The importance of steatosis is also discussed both at the early phase and advanced phase. Finally he reviews the association with HCC and CV risks.
Read MoreThe complex interaction between body weight and NAFLD / NASH
NAFLD is strongly associated with obesity and metabolic disease. Obesity has clinical implications that extend beyond the liver. It is associated with insulin resistance which plays an important role in NASH. Agents with combined PPAR agonism may hold significant potential in this regard.
Read MoreDefining comprehensive models of care for NAFLD Liver health specialists
NAFLD places a substantial burden on healthcare systems and receives little attention from public health authorities. Ambitious measures are needed to improve preparedness globally. Prof Lazarus, Spain, discusses how to establish care pathways tailored to meet patients needs but also that optimally use existing resources. Modifiable risks factors are particularly important in a comprehensive strategy.
Read MoreHCC in Patients with NAFLD/NASH
Prof Bugianesi, Italy, reviews a burning issue: hepatocellular carcinoma (HCC) in patients with NAFLD/ NASH. She reviews the epidemiology globally and impact on liver transplant. There are multiple risks factors for HCC in NASH patients such as obesity, type 2 diabetes (T2D), and the metabolic syndrome in general. For clinicians, she presents the main studies, the profiles of the patients particularly at risk and risk stratifications strategies.
Read MoreNASH and quality of life
Prof Schattenberg, Germany, reviews how NASH impacts quality of life. He presents the mechanisms underlying metabolic comorbidities in NASH and discusses the relevant NASH phenotypes. A presentation of the tools that can be used to review health-related quality of life (HQRL) is particularly relevant for clinicians.
Read MoreNASH is part of a multi-system disorder
Prof Sanyal, USA, reminds us that NAFLD is the most common liver disease and reviews the comorbidities associated with NAFLD, and particularly the association with cardiovascular disease. He makes the point that NASH is part of a multi-system disorder and also presents the key concepts related to management, including risk stratification. An important learning is not to miss opportunities of early identification of patients at risks to improve the patients’ journey.
Read MoreFrom number-one liver disease to multi-system disease: NASH, a major unmet clinical need
In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.
Read MoreImaging biomarkers in NAFLD: Could they avoid liver biopsy
There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
Read MoreInflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany
As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.
Read More